0000835887-13-000052.txt : 20130605 0000835887-13-000052.hdr.sgml : 20130605 20130605120816 ACCESSION NUMBER: 0000835887-13-000052 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130605 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130605 DATE AS OF CHANGE: 20130605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROGENICS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000835887 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133379479 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23143 FILM NUMBER: 13893554 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9147892800 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 8-K 1 form8_k06052013.htm FORM 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) June 5, 2013
 
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-23143
 
13-3379479
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
 
 
 
 
777 Old Saw Mill River Road, Tarrytown, New York
 
10591
(Address of principal executive offices)
 
(Zip Code)
Registrant's telephone number, including area code (914) 789-2800
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


Item 8.01.
Other Events.
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) chief executive officer Mark R. Baker is presenting today at the Jefferies Global Healthcare Conference in New York City. The company overview will be webcast live at 3:00 PM EDT via a link on the Events page of Progenics' website and archived there for 30 days.
A copy of the Company's press release relating to this event is included in this Report as Exhibit 99.1, and the information contained therein is incorporated into this Item 8.01 by this reference.

Item 9.01.
Financial Statements and Exhibits.


(d)  
Exhibits
 
Exhibit No.
Description

99.1





 


 
 
 




 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
PROGENICS PHARMACEUTICALS, INC.
 
By:
/s/ ANGELO W. LOVALLO, JR.
 
 
Angelo W. Lovallo, Jr.
 
 
Vice President, Finance & Treasurer
 
 
(Principal Financial and Accounting Officer)
 
 
 
Date: June 5, 2013


 GRAPHIC 2 image0.jpg begin 644 image0.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#K/&WAN+P_ MH7VVSO;KS/,5-KMD156/XGI=:[%8V>ERSP22;%<'YF]P/2 MM/;0LM3B668IMKEV5]UL>B#Z4<5BZ]XEL/#MJDMXS&1^(X4&7<^@%8Q\2^)C M!]KC\,/]GQN"-*-Y'KBJ=2*T,J>$JU(\R5EYM+\SM#]!2#Z"N8\->-K#Q%(] MMY;VMZGWX)>OX>M:^KZS9Z'I[WM[)LB7\R?0"FI)J]]")X>K"I[*47S=B^<9 M`Q2YKAX_&.NW=H=0LO#U MCM_F;_V=B+.5M%OJM/74[P=.F*.U9U[K-KI6E?;[]OL\87+*QR0?[ON:YN/Q M;KU]`;S3O#CR6?5&DDVLX]0*J4XQ,J6%JU5>-DN[:2^]G:]NU&1W%>3A#GWH]I&W-?0:P5=U?8\ MOO=M#K1C%`Z]*X*#XB27EA')8:)=7-TP^=$^XG_`N]5['XFRC54LM6TM[3>V MW=DY7/0D'M4JM`V_LS%>][NJW5U<]$;!XXS7`R>'/$1^(J:L)X_L0/W\\A,? M=Q79W]VUE8O=1V\EP5&1'%R6^E/Y;GQ+;Z1+H\ULTK;296`8>^**C@[7 M#!+$14Y44FK-/;;J=R.G`I,CT%-D=8T9B0%')).,5R#^-Y+Z_DLM`TR746B. M))L[8U/IFKE)1W.6E0J56^1:+[CLL^M''?%<3)XTU/3+ZVM]:T)[=+B01I+' M(&&36UXB\2V?ARV26Y#R2RG;%"GWG-+VB-'@ZRE&-KWVM9W-O'S9P*<*X>[\ M6>(;"P;4;GPX%M%&YL3C>%]2*ZK3M4CO].@NU1U$R!PN,XS34U+853"U*:YG M:WDT_P`CE/BG_P`BET_Y;)65X4\,WNH^&;6XB\07MK&X.(8B,+]*N_$[4+.; MPOY4-W"\GG*=JN"<5?\``%_9+X3L(&NX1-@Y0N`W7TK!J+K:]CU8SJ4LL7*M M>;M?IYC]-^'^EV=VMY>23ZAE*.E1RRQ0(9)9$C4=6 M8X`K>,5%61X]6M4K.\VVSR*_T^#5?B[-9W.3"[Y90<9PN:]7BTZSB:)H[6%7 MB&$94`*CVKRU+RV'QB:Y^T1>221YFX;?N^M>KP3PW">9!*DB?WD8$5C12][U M/2S251*DNG*CR:24ZU\7XX[D[HH92L:GH-HZ5Z]GCZ5X_P"*K6X\+>/8==\M MFLY)0^]1TS]X5ZC9ZQIU]9+=P7D!A8;MV\ M7L+$*))A]UL'.`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`DLMG_P`! M_E7>V6MZ8MC;JVH6H(C7(\T>E>=ZG>VK_%VTN4N8C`-N9`XVCCUJJS5H^ICE MD)*K5NOLR.J^)>IRZ=X5D2%BKW+B+=Z#O5GP!90V?@^R,:@&4>8Y[DFF>.M* M_P"$A\+/]B*S21'S8]ASNQU`KGOA]XPLX--&CZE,+>:!B(S)P&'H?0BAR2K> M\*%*53+6J2NU+5+<[C6=#M=:2V6Y+`6\PF0J>XKC/B7HNHW-S9:M8QM-]F&& M11DKSD-CO767?BK1;/:)=0B=W("QQ'>QS["J6K>)FTSQ5I>GR&)+2\C)9GX( M;M^%5547%IZ&&"EB*-6,E&]KV3VM;4YRQ^(FE:Q9-IFO6[VIE7RY''W3_45W MNGVUE;Z?!#:2`VZ(!&0VG?\(=X?)S_9F:M\>M'':A12V1I.O4FK2DVO4KW-I;WD+07,*2Q-U5QD&L`_#_PR9"_ M]G`9.2H=@OY9KI_U#BGNATZ]6FK0DTO)E6SL+33K=;>SMTAB'\*+BO/ M_B!)9:YJ]GH-K`9=4##$H.!$#U!_"O2>!W%>9^(M$U71/%Y\3V$0N8"V7CW8 M(XP1659/ELEZG=E?066YA9/-A#;<*QP&'J*V?&0BM]"L[6-_+"W,07'4*#U_ M"H?$6GVMMHES>-=AWRJ,H-KF;6C?D=#IVCZ M;I,6+"SA@![JO)_&H;GPWHM_<-ZJDN#Z?6JYXVM8B&'K-^T4G?O\` MTSMK3PYH^G7`N;2RA@E`P'7K@U&WA'0))&=]+@9F.6..IKG=1L[&'5Y[59I1 M"NG,ZCS6^_G(/UJLES;V`LKCSIF^T:<[3JLAR[#&",]#2O'K8(TZS?/&N*XX:HRI?FWFQ;9MY)!&[';$?O M$9[^M:6I7%C%<63V=SC2II")V+,5#8^7WQ1[C5[(IT\0IU^YV5G96V MG6RVMG"L4*]$7H/I65J?A/P_JESOO+"%IVYW*=K'WXKGDEATO4K`W&H236TU MK-&)22`Q[#'J/6H=,DM7N=!N+R4E3!+'O9CRP/`_*ARBU9HB%&K!NI&3]5?7 M?_(Z70=!T:P5Y[/2!:R*Y7=*,L0.X)[5>U/0],UI%74+..?`PI;J/H:XJWU! M(E@6ZG?^S?[0E$IWDX_N#UQGM3M=OK&*.:WLY'W)")(97D;NW11[>]/FC:UM M"W0K2JJ7,^9]==.F]S4TGP[X?AUVZMH])"S6@5@\K[P0>A`/2NR0`*`.E>>W M5S'<7]ZRWX@>2*W"R$$ACCD-WQ44=U?%/D\/:I,N2!);W3"-N>J^U*$DMD%7 ,#SJN\I/9;^GFS__9 ` end EX-99.1 3 ex99_10605213.htm EXHIBIT 99.1
Exhibit 99.1
 
 
777 Old Saw Mill River Road
Tarrytown, New York 10591
 
 (914) 789-2800
www.progenics.com

Contact:
 
Kathleen Fredriksen
Corporate Development
(914) 789-2871
kfredriksen@progenics.com
 

Progenics Pharmaceuticals to Present at Jefferies Healthcare Conference
TARRYTOWN, N.Y., May 31, 2013 — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a presentation on Wednesday, June 5th at 3:00 PM EDT at the Jefferies Global Healthcare Conference in New York City. The company overview will be webcast live via a link on the Events page of Progenics' website and archived there for 30 days.

About Progenics
Progenics Pharmaceuticals, Inc. develops innovative medicines for oncology, and has a pipeline that includes product candidates in preclinical through late-stage development. Progenics' first commercial product, Relistor® (methylnaltrexone bromide) for opioid-induced constipation, is marketed and in further development by Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. is developing the subcutaneous formulation. For additional information, please visit www.progenics.com.

Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this announcement.

(PGNX-G)